TABLE 3.
Divalproex Group (N=14) |
Placebo Group (N=13) |
|||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Baseline |
End of Stimulant Monotherapy Lead-In Phase |
End of Randomized, Controlled Trial Phase |
Baseline |
End of Stimulant Monotherapy Lead-In Phase |
End of Randomized, Controlled Trial Phase |
|||||||
Measure | Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD |
Retrospective-Modified Overt Aggression Scale score | 62.13 | 42.63 | 41.80 | 25.79 | 32.13 | 44.14 | 61.54 | 28.98 | 53.31 | 29.50 | 35.77 | 28.86 |
Logarithmically transformed (loge) score | 3.93 | 0.68 | 3.62 | 0.52 | 2.48 | 1.72 | 4.04 | 0.47 | 3.87 | 0.49 | 3.36 | 0.74 |
Conners' Global Index T score | 80.60 | 6.49 | 72.80 | 13.67 | 65.13 | 15.60 | 77.46 | 7.66 | 67.54 | 9.10 | 71.50 | 13.17 |